Arvanitis, L. A., Miller, B. G. & Seroquel Trial 13 Study Group (1997) Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbations of schizophrenia: a comparison with haloperidol and placebo. Biological Psychiatry, 42, 233–246.
Ataya, K., Mercado, A., Kartaginer, J., et al (1988) Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertility and Sterility, 50, 876–881.
Barnes, T. R. E. & Harvey, C. A. (1993) Psychiatric drugs and sexuality. In: Sexual Pharmacology (eds Riley, A. J., Peet, M. & Wilson, C.), pp. 176–196. Oxford: Clarendon Press.
Bergemann, N. (2001) Hypooestrogenism in schizophrenic women. Archives of Women's Mental Health, 3 (suppl. 2), s154.
Beumont, P. J. V., Gelder, M. G., Friesen, H. G., et al (1974) The effects of phenothiazines on endocrine function: I. Patients with inappropriate lactation and amenorrhoea. British Journal of Psychiatry, 124, 413–419.
Bole-Feysot, C., Goffin, V., Edery, M., et al (1998) Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocrine Reviews, 9, 225–268.
Breier, A. F., Malhotra, A. K., Tung-Ping, S., et al (1999) Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side-effects, and neuroendocrine response. American Journal of Psychiatry, 156, 294–298.
Brown, W. A. & Laughren, T. (1981) Tolerance to the prolactin-elevating effect of neuroleptics. Psychiatry Research, 5, 317–322.
Canuso, C. M., Goldstein, J. M., Wojcik, J., et al (2002) Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Research, 111, 11–20.
Checkley, S. (1991) Neuroendocrine effects of psychotropic drugs. Baillière's Clinical Endocrinology and Metabolism, 5, 15–33.
Crawford, A. M., Beasley, C. M. & Tollefson, G. D. (1997) The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research, 26, 41–54.
David, S. R., Taylor, C. C., Kinon, B. J., et al (2000) The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clinical Therapeutics, 22, 1085–1096.
Dinan, T. G. (1999) The physical consequences of depressive illness. BMJ, 318, 826.
Finn, S. E., Bailey, J. M., Schultz, R. T., et al (1990) Subjective utility ratings of neuroleptics in treating schizophrenia. Psychological Medicine, 20, 843–848.
Ghadirian, A. M., Chouinard, G. & Annable, L. (1982) Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. Journal of Nervous and Mental Disease, 170, 463–467.
Goodnick, P. J., Rodriguez, L. & Santana, O. (2002) Antipsychotics: impact on prolactin levels. Expert Opinion in Clinical Pharmacotherapy, 3, 1381–1391.
Green, A. L. & Brown, W. A. (1988) Prolactin and neuroleptic drugs. Endocrinology and Metabolism Clinics of North America, 17, 213–223.
Gruen, P. H., Sachar, E. J., Altman, N., et al (1978) Relation of plasma prolactin to clinical response in schizophrenic patients. Archives of General Psychiatry, 35, 1222–1227.
Gruender, G., Wetzel, H., Schloesser, R., et al (1999) Neuroendocrine response to antipsychotics: effects of drug type and gender. Biological Psychiatry, 45, 89–97.
Haddad, P. & Wieck, A. (2000) Antidepressant-induced hyperprolactinaemia. Journal of Psychopharmacology, 14 (suppl. 3), A28.
Haddad, P., Hellewell, J. S. E. & Wieck, A. (2001) Antipsychotic-induced hyperprolactinaemia: a series of illustrative case reports. Journal of Psychopharmacology, 15, 293–295.
Halbreich, U., Rojansky, N., Palter, S., et al (1995) Decreased bone mineral density in medicated psychiatric patients. Psychosomatic Medicine, 57, 485–491.
Hellewell, J. S. E. (1998) Antipsychotic tolerability: the attitudes and perceptions of medical professionals, patients and caregivers towards side-effects of antipsychotic therapy. European Neuropsychopharmacology, 8, S248.
Hopper, J. L. & Seeman, E. (1994) The bone density of female twins discordant for tobacco use. New England Journal of Medicine, 330, 387–392.
Ismail, K., Murray, R. M., Wheele, M. J., et al (1998) The dexamethasone suppression test in schizophrenia. Psychological Medicine, 28, 311–317.
Kapur, S. & Seeman, P. (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. American Journal of Psychiatry, 158, 360–369.
Kim, Y. K., Kim, L. & Lee, M. S. (1999) Risperidone and associated amenorrhea: a report of 5 cases. Journal of Clinical Psychiatry, 60, 315–317.
Kinon, B. & Gilmore, J. (2001) Prevalence of hyperprolactinemia in a large cohort of schizophrenic patients treated with conventional antipsychotic drugs or risperidone. Archives of Women's Mental Health, 3 (suppl. 2), S185.
Kleinberg, D. L., Davis, J. M., De Coster, R., et al (1999) Prolactin levels and adverse effects in patients treated with risperidone. Journal of Clinical Psychopharmacology, 19, 57–61.
Klibanski, A. & Greenspan, S. L. (1986) Increase in bone mass after treatment of hyperprolactinemic amenorrhea. New England Journal of Medicine, 315, 542–546.
Koppelman, M. C. S., Kurtz, D. W., Morrish, K. A., et al (1984) Vertebral bone mineral density content in hyperprolactinemic women. Journal of Clinical Endocrinology and Metabolism, 59, 1050–1053.
Kuruvilla, A., Peedicayil, J., Srikrishna, G., et al (1992) A study of serum prolactin levels in schizophrenia: comparison of males and females. Clinical and Experimental Pharmacology and Physiology, 19, 603–606.
Linkowski, P., van Cauter, E., L'Hermite-Baleriaux, M., et al (1989) The 24-hour profile of plasma prolactin in men with major endogenous depressive illness. Archives of General Psychiatry, 46, 813–819.
Lundberg, P. O. & Hulter, B. (1991) Sexual dysfunction in patients with hypothalamo-pituitary disorders. Experimental and Clinical Endocrinology, 98, 81–88.
Magharious, W., Goff, D. C. & Amico, E. (1998) Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Research, 77, 159–166.
Meltzer, H. Y. & Fang, V. S. (1976) The effect of neuroleptics on serum prolactin in schizophrenic patients. Archives of General Psychiatry, 33, 279–286.
Meltzer, H. Y., Goode, D. J., Schyve, P. M., et al (1979) Effect of clozapine on human serum prolactin levels. American Journal of Psychiatry, 136, 1550–1555.
Meltzer, H. Y., Kane, J. M. & Kolakowska, T. (1983) Plasma levels of neuroleptics, prolactin levels, and clinical response. In Neuroleptics: Neurochemical, Behavioral, and Clinical Perspectives (eds Coyle, J. T. & Enna, S. J.), pp. 225–279. New York: Raven Press.
Mizuchi, A., Kitagawa, N. & Miyachi, Y. (1983) Regional distribution of sultopride and sulpiride in rat brain measured by radioimmunoassay. Psychopharmacology, 81, 195–198.
Molitch, M. E. (1995) Prolactin. In The Pituitary (ed. Melmed, S.), pp. 136–186. Cambridge: Blackwell Science.
Oseko, F., Morikawa, K., Motohashi, T., et al (1988) Effects of chronic sulpiride-induced hyperprolactinemia on menstrual cycles of normal women. Obstetrics and Gynecology, 72, 267–271.
Parfitt, A. M. (1994) Osteonal and hemi-osteonal remodelling: the spatial and temporal framework for signal traffic in adult human bone. Journal of Cell Biochemistry, 55, 273–286.
Peters, F., Del Pozo, E., Conti, A., et al (1986) Inhibition of lactation by a long-acting bromocriptine. Obstetrics and Gynecology, 67, 82–85.
Peris, P., Pares, A., Guanabens, N., et al (1992) Reduced spinal bone mass and deranged bone mineral metabolism in chronic alcoholics. Alcohol and Alcoholism, 27, 619–625.
Peuskens, J. (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry, 166, 712–726.
Polishuk, J. L. & Kulcsar, S. (1956) Effects of chlorpromazine on pituitary function. Journal of Clinical Endocrinology, 16, 292–293.
Prentice, D. S. & Deakin, J. F. W. (1992) Role of neuroleptic drugs and organic mechanisms in the aetiology of menstrual irregularities in schizophrenic women. Schizophrenia Research, 6 (special issue), 114.
Rao, M. L., Gross, G., Strebel, B., et al (1994) Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biological Psychiatry, 35, 151–163.
Rao, M. L., Strebel, B., Halaris, A., et al (1995) Circadian rhythm of vital signs, norepinephrine, epinephrine, thyroid hormone, and cortisol in schizophrenia. Psychiatry Research, 57, 21–39.
Reavley, A., Fisher, A. D., Owen, D., et al (1997) Psychological distress in patients with hyperprolactinaemia. Clinical Endocrinology, 47, 343–347.
Rivera, J. L., Lal, S., Ettigi, P., et al (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clinical Endocrinology, 5, 273–282.
Royal College of Physicians (1999) Osteoporosis: Clinical Guidelines for Prevention and Treatment.
London: Royal College of Physicians.
Schlechte, J., El-Khoury, G., Kathol, M., et al (1987) Forearm and vertebral bone mineral density in treated and untreated hyperprolactinemic amenorrhea. Journal of Clinical Endocrinology and Metabolism, 64, 1021–1026.
Small, J. G., Hirsch, S. R., Arvanitis, L. A., et al (1997) Quetiapine in patients with schizophrenia: a high-and low-dose double-blind comparison with placebo. Archives of General Psychiatry, 54, 549–557.
Smith, S., Wheeler, M. J., Murray, R., et al (2002) The effects of antipsychotic-induced hyperprolactinemia on the hypothalamic–pituitary–gonadal axis. Journal of Clinical Psychopharmacology, 22, 109–114.
Sobrinho, L. G. (1993) The psychogenic effects of prolactin. Acta Endocrinologica, 129 (suppl. 1), 38–40.
Tollefson, G. D. & Kuntz, A. J. (1999) Review of recent clinical studies with olanzapine. British Journal of Psychiatry, 174 (suppl. 37), 30–35.
Tuomisto, J. & Mannisto, P. (1985) Neurotransmitter regulation of anterior pituitary hormones. Pharmacological Reviews, 37, 249–301.
Turkington, R. W. (1972) Prolactin secretion in patients treated with various drugs. Archives of Internal Medicine, 130, 349–354.
van de Kar, L. D. (1991) Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Annual Review of Pharmacology and Toxicology, 31, 289–320.
Veldhuis, J. D. & Johnson, M. L. (1988) Operating characteristics of the hypothalamo–pituitary–gonadal axis in men: circadian, ultradian, and pulsatile release of prolactin and its temporal coupling with luteinizing hormone. Journal of Clinical Endocrinology and Metabolism, 67, 116–123.
von Bardeleben, U., Benkert, O. & Holsboer, F. (1987) Clinical and neuroendocrine effects of zotepine – a new neuroleptic drug. Pharmacopsychiatry, 20, 28–34.
Wesselmann, U. & Windgassen, K. (1995) Galactorrhea: subjective response by schizophrenic patients. Acta Psychiatrica Scandinavica, 91, 152–155.
Windgassen, K., Wesselmann, U. & Schulze Monking, H. (1996) Galactorrhoea and hyperprolactinaemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology, 33, 142–146.
Wistedt, B., Wiles, D. & Kolakowska, T. (1981) Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatments with depot neuroleptics. Lancet, i, 1163.
Wode-Helgodt, B., Eneroth, P., Fryo, B., et al (1977) Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Acta Psychiatrica Scandinavica, 56, 280–293.
Zelaschi, N. M., Delucchi, G. A. & Rodriguez, J. L. (1996) High plasma prolactin levels after long-term neuroleptic treatment. Biological Psychiatry, 39, 900–901.